CMS Official Cites OCM as Example of Biosimilar Success
February 21st 2022Purva Rawal, PhD, senior advisor and chief strategy officer, Center for Medicare and Medicaid Innovation, addressed attendees at the Association for Accessible Medicines' Access! annual meeting, held in Orlando, Florida, February 15-16.
Experts Discuss How Employers Can Take on HSA HDHP Challenges While Encouraging Value-Based Care
February 20th 2022Speaking during a webinar presented by the National Alliance of Healthcare Purchaser Coalitions, experts weighed the pros and cons of employer high-deductible health plans (HDHPs) and outlined steps to address challenges raised.
Payers, Value-based Care Policies Impact Biosimilar Adoption, Cardinal Health Report Finds
February 8th 2022Cardinal Health's report, “2022 Biosimilars Report: The U.S. Journey and Path Ahead,” outlines how biosimilars will move beyond their comfort zones in oncology and rheumatology and more boldly into therapeutic areas such as ophthalmology and diabetes care.
MA Primary Care Payment Models Influenced Telemedicine Usage During the Pandemic, Research Shows
July 16th 2021Larger primary care practices in downside risk–only payment models and capitation saw the highest telemedicine utilization rates by their patients enrolled in Medicare Advantage (MA) plans.
2 Commerce Drive
Suite 100
Cranbury, NJ 08512
© 2024 MJH Life Sciences® and AJMC®.
All rights reserved.